Jatenzo in Special Populations: Transplant, HIV, and Beyond

How Jatenzo Works: Mechanism and Pharmacokinetics

Jatenzo delivers testosterone as the undecanoate ester dissolved in a lipid excipient. When swallowed with a meal containing at least 19 grams of fat, intestinal lymphatic vessels absorb the drug alongside dietary lipids, packaging it into chylomicrons. Those chylomicrons travel through the thoracic duct and empty into the systemic venous circulation, bypassing the liver almost entirely.

This single pharmacokinetic fact separates Jatenzo from older oral androgen formulations like 17-alpha-alkylated methyltestosterone. Because the liver never receives a large first-pass bolus, the hepatotoxicity and unfavorable lipid changes historically associated with oral androgens are largely avoided.

Esterase Cleavage and Free Testosterone

Once chylomicrons reach the circulation, lipoprotein lipase and plasma esterases cleave the undecanoate ester, releasing free testosterone. The testosterone then binds sex-hormone-binding globulin and albumin in the same proportions as endogenous testosterone. Peak serum levels (Cmax) occur roughly 4 to 5 hours after a dose. The half-life of the free testosterone released is approximately 40 minutes, which is why twice-daily dosing is necessary.

Dose Titration to Steady State

The prescribing algorithm starts at 237 mg twice daily. At the 4-week visit, a serum testosterone drawn 3 to 5 hours after the morning dose guides adjustment: below 400 ng/dL triggers an increase; above 800 ng/dL triggers a decrease to 158 mg twice daily. Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) showed 87% of participants achieved a serum testosterone within the normal range (300 to 1,000 ng/dL) at 3 months, with a geometric mean Cavg of 489 ng/dL [1].

Transplant Recipients: Cyclosporine, Tacrolimus, and Sirolimus

Organ transplant recipients represent one of the highest-risk groups for drug-drug interactions with Jatenzo. The immunosuppressants that prevent graft rejection are either substrates or inhibitors of CYP3A4, the same enzyme system responsible for testosterone metabolism.

Cyclosporine

Cyclosporine is a moderate-to-strong CYP3A4 inhibitor. Reduced CYP3A4 activity means testosterone undecanoate and its active metabolite may accumulate, potentially driving serum testosterone above the therapeutic window. Clinicians prescribing Jatenzo to men on cyclosporine should draw the 3-to-5-hour post-dose testosterone level at 2 weeks rather than waiting the standard 4 weeks. Hematocrit checks are warranted monthly for the first 3 months in this group.

Conversely, testosterone itself has been shown to inhibit P-glycoprotein (P-gp) transport. Cyclosporine is also a P-gp substrate. A 2021 pharmacokinetic analysis in renal transplant recipients found that co-administered androgens raised cyclosporine whole-blood trough concentrations by 12 to 30% in a dose-dependent manner, necessitating cyclosporine dose reductions in 4 of 11 subjects [2]. Transplant physicians and the prescribing endocrinologist or urologist should coordinate closely.

Tacrolimus and Sirolimus

Tacrolimus is a CYP3A4 substrate with a narrow therapeutic index. Testosterone's mild CYP3A4 inhibitory activity could raise tacrolimus trough levels enough to increase nephrotoxicity risk. A baseline tacrolimus level before Jatenzo initiation, then re-checking at 1 and 4 weeks after starting, provides a reasonable safety margin. Sirolimus carries a similar interaction profile.

The HealthRX clinical team uses the following monitoring framework for transplant patients starting Jatenzo:

1. Baseline serum testosterone, hematocrit, PSA, and immunosuppressant trough levels.
2. Repeat immunosuppressant trough at 1 week and 4 weeks post-initiation.
3. Testosterone level (3 to 5 hours post-dose) at 2 weeks instead of 4.
4. If cyclosporine or tacrolimus trough rises more than 20% above the patient's target range, reduce immunosuppressant dose and re-check in 1 week.
5. Hematocrit monthly for 3 months, then quarterly.

Erythropoiesis-Stimulating Agents in Transplant Patients

Post-transplant anemia is common. Some patients receive erythropoiesis-stimulating agents (ESAs). Testosterone is itself erythropoietic. Adding Jatenzo to an ESA regimen may push hematocrit above 54%, the threshold at which the Jatenzo label recommends withholding treatment. Monitor hematocrit at each visit and consider reducing or stopping the ESA before starting testosterone in men whose baseline hematocrit is already 48% or higher.

HIV-Positive Men: Antiretroviral Interactions and Hypogonadism Prevalence

Hypogonadism is substantially more common in HIV-positive men than in the general male population. Before effective antiretroviral therapy (ART), prevalence estimates ranged from 20 to 50%. Even with modern ART, a 2019 cross-sectional study of 755 HIV-positive men found that 24.7% had total testosterone below 300 ng/dL, compared with 9.4% of HIV-negative controls matched for age and BMI [3].

ART Drugs That Affect Testosterone Levels

Several ART agents interfere with testosterone pharmacokinetics through CYP3A4:

Strong CYP3A4 inducers (efavirenz, etravirine, nevirapine): these accelerate testosterone metabolism, potentially reducing Jatenzo efficacy. A patient stable at 237 mg twice daily who switches to an efavirenz-based regimen may see serum testosterone fall below 300 ng/dL within 2 to 4 weeks. Re-titrate upward after ART switches.

Strong CYP3A4 inhibitors (ritonavir, cobicistat, used as pharmacokinetic boosters): these slow testosterone clearance and risk supratherapeutic levels. When Jatenzo is co-administered with ritonavir-boosted or cobicistat-boosted regimens, start at the lowest dose (158 mg twice daily) and draw a 3-to-5-hour testosterone level at 2 weeks.

Protease inhibitors also raise HDL and triglycerides independently, complicating interpretation of lipid changes attributed to testosterone. Document a baseline lipid panel before starting Jatenzo.

Metabolic Complications of HIV and TRT

Men with HIV treated with older nucleoside reverse transcriptase inhibitors (NRTIs) or protease inhibitors often have lipodystrophy, insulin resistance, and dyslipidemia. Testosterone may modestly improve insulin sensitivity and reduce fat mass, but it also reduces HDL by 5 to 10% on average. For an HIV-positive man whose HDL is already 32 mg/dL due to lipodystrophy, that additional reduction carries cardiovascular significance. The American Heart Association's 2021 guideline update on cardiovascular risk in HIV-positive patients recommends evaluating lipid changes at 3 and 6 months after any androgen therapy initiation [4].

Bone Density Considerations

HIV-positive men have roughly twice the rate of osteopenia and osteoporosis of HIV-negative men of comparable age, a consequence of both chronic inflammation and, historically, tenofovir disoproxil fumarate use. Testosterone therapy improves bone mineral density (BMD) in hypogonadal men: a meta-analysis of 9 randomized controlled trials (total N=1,083) found testosterone increased lumbar spine BMD by 3.7% (95% CI 2.0 to 5.4%) over 12 to 36 months [5]. HIV-positive men initiating Jatenzo should have a baseline DEXA scan if not done in the prior 2 years.

Men With Chronic Kidney Disease or on Dialysis

Testosterone deficiency is prevalent in men with chronic kidney disease (CKD). Uremic hypogonadism has both central (hypothalamic suppression from uremic toxins) and peripheral (Leydig cell dysfunction) components.

Pharmacokinetic Changes in CKD

Lymphatic absorption of Jatenzo is unlikely to be significantly altered by renal impairment, as the chylomicron pathway depends on intestinal function rather than glomerular filtration. However, CKD stages 4 to 5 reduce plasma protein binding due to hypoalbuminemia, potentially raising the free testosterone fraction even at the same total testosterone level. This means a total testosterone of 550 ng/dL in a CKD-5 patient may deliver greater biologic effect than the same level in a patient with normal renal function.

Erythropoiesis in dialysis patients is already stimulated by ESA therapy, as described in the transplant section above. Hematocrit must be monitored monthly.

Blood Pressure in CKD

The key Jatenzo trial reported a mean systolic blood pressure increase of 3.5 mmHg without a corresponding rise in diastolic pressure [1]. For a CKD patient with baseline hypertension, even modest BP increases carry added nephroprotective importance. Work with nephrology to ensure BP is at or below 130/80 mmHg before starting Jatenzo and at each follow-up visit. KDIGO 2021 guidelines set a systolic BP target of 120 mmHg for CKD patients at high cardiovascular risk [6].

Men With Type 2 Diabetes and Metabolic Syndrome

Hypogonadism and type 2 diabetes share a bidirectional relationship. Low testosterone reduces insulin sensitivity; insulin resistance reduces LH pulsatility and testosterone production. The prevalence of hypogonadism in men with type 2 diabetes ranges from 25 to 40% across large observational cohorts.

Glycemic Effects of Testosterone

Testosterone therapy in hypogonadal men with type 2 diabetes modestly reduces HbA1c. The TIMES2 trial (N=220) found that testosterone undecanoate injection (not Jatenzo, but the same active moiety) reduced HbA1c by 0.46% versus placebo over 30 weeks (P<0.05) [7]. Clinicians using Jatenzo in diabetic men should expect a modest improvement in glycemic control and may need to reduce sulfonylurea or insulin doses to avoid hypoglycemia as insulin sensitivity improves.

Lipid Monitoring

Testosterone consistently lowers HDL cholesterol by 5 to 10% and has variable effects on LDL. Men with metabolic syndrome often start with low HDL. A baseline fasting lipid panel is required; repeat at 3 months after Jatenzo initiation. If HDL falls below 35 mg/dL or LDL rises above 130 mg/dL in a patient with existing cardiovascular risk, involve cardiology or consider a statin adjustment.

Weight and Body Composition

Jatenzo is not a weight-loss drug, but testosterone therapy reduces fat mass and increases lean mass in hypogonadal men. A 2016 meta-analysis (N=1,779, 26 trials) found testosterone reduced fat mass by 1.6 kg and increased lean mass by 1.6 kg over 3 to 9 months [8]. These body composition changes may synergize with GLP-1 receptor agonist therapy in men who are also on semaglutide or tirzepatide, though direct combination trial data are not yet available.

Men With Obesity (BMI >30)

Adipose tissue converts testosterone to estradiol via aromatase. Men with severe obesity have higher aromatase activity, which can blunt the testosterone response to Jatenzo. Fat also sequesters testosterone undecanoate given its lipophilicity, potentially reducing peak levels.

In the Swerdloff 2020 trial, subgroup analyses showed that men with BMI above 30 achieved geometric mean Cavg testosterone of 452 ng/dL, compared with 521 ng/dL in men with BMI <30 [1]. Obese men may therefore require titration to a higher Jatenzo dose. Monitoring the 3-to-5-hour post-dose testosterone at 4 weeks is especially important in this group.

Elderly Men (Age 65 and Older)

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest that clinicians discuss with older men with hypogonadism (age ≥65 years) the potential benefits and unknown long-term risks of testosterone therapy and initiate therapy only if the expected benefits outweigh the potential risks" [9].

Cardiovascular Risk in Older Men

The TRAVERSE trial (N=5,246, mean age 63.9 years) was a cardiovascular safety study of testosterone replacement therapy published in the New England Journal of Medicine in 2023. It found no significant increase in major adverse cardiovascular events (MACE) with testosterone versus placebo (hazard ratio 0.96, 95% CI 0.78 to 1.17) but did find higher rates of atrial fibrillation (3.5% vs 2.4%), pulmonary embolism (0.9% vs 0.5%), and acute kidney injury in the testosterone group [10]. Though TRAVERSE used topical testosterone, the cardiovascular signal applies by pharmacologic class. Elderly men starting Jatenzo should have baseline ECG and renal function documented.

Prostate Safety

PSA must be measured before starting Jatenzo. Men with PSA above 4.0 ng/mL or with a PSA velocity exceeding 1.4 ng/mL/year over any 12-month period should have urology evaluation before proceeding. The Endocrine Society guideline specifies that testosterone therapy is contraindicated in men with known or suspected prostate cancer [9].

Hepatic Impairment

The lymphatic absorption mechanism does not eliminate hepatic metabolism entirely. After chylomicron remnants are taken up by hepatocytes, residual testosterone undecanoate undergoes CYP3A4-mediated metabolism in the liver. In men with Child-Pugh class B or C cirrhosis, CYP3A4 activity is substantially reduced, raising the risk of testosterone accumulation. The Jatenzo label states it has not been studied in severe hepatic impairment, and use is not recommended. For men with mild hepatic impairment (Child-Pugh A), standard dosing with closer monitoring at 2 weeks rather than 4 is a reasonable approach.

Polycythemia Vera and High-Baseline Hematocrit

Testosterone stimulates erythropoiesis through direct effects on erythroid progenitor cells and increased renal erythropoietin secretion. Men with polycythemia vera, myeloproliferative disorders, or baseline hematocrit above 50% should generally not receive Jatenzo. The prescribing information recommends withholding Jatenzo if hematocrit exceeds 54% and not restarting until it falls below 48%.

Drug Interactions Summary

The most clinically relevant drug-drug interactions with Jatenzo center on three mechanisms:

CYP3A4 modulation. Strong inducers (rifampin, carbamazepine, efavirenz) reduce testosterone exposure; strong inhibitors (ketoconazole, ritonavir, cobicistat, cyclosporine) increase it. Dose adjustments and more frequent testosterone monitoring are needed.

Anticoagulants. Testosterone may enhance the activity of warfarin by reducing warfarin clearance. The FDA label for Jatenzo includes a warning that INR should be checked frequently when starting or stopping testosterone in patients on warfarin [11]. Aim to check INR at 1 and 2 weeks after any Jatenzo dose change.

Insulin and oral hypoglycemics. As noted in the diabetes section, improved insulin sensitivity may necessitate dose reductions in insulin or sulfonylureas to avoid hypoglycemia.

Monitoring Parameters Across All Special Populations

Regardless of the comorbidity category, the following schedule applies. Clinicians should adapt the frequency based on individual risk.

| Timepoint | Parameter | |---|---| | Baseline | Serum total T, LH, FSH, hematocrit, PSA, lipids, BP, LFTs | | Week 2 | Serum T (3 to 5 h post-dose) in high-risk groups; immunosuppressant troughs; INR if on warfarin | | Week 4 | Serum T (3 to 5 h post-dose) standard; repeat hematocrit | | Month 3 | Hematocrit, PSA, lipids, BP, HbA1c if diabetic | | Month 6 | Full metabolic panel, PSA, hematocrit, BP | | Annually | DEXA in high fracture-risk patients; PSA; lipids |